Zynex (NASDAQ:ZYXI) Cut to “Neutral” at LADENBURG THALM/SH SH

Zynex (NASDAQ:ZYXI) was downgraded by LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a research report issued on Wednesday,Briefing.com Automated Import reports.

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Zynex in a research report on Friday, December 6th.

Zynex Stock Performance

Shares of ZYXI stock opened at $7.00 on Wednesday. Zynex has a 12 month low of $4.36 and a 12 month high of $13.19. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. The firm has a market capitalization of $222.92 million, a P/E ratio of 46.67 and a beta of 0.81. The company’s fifty day moving average price is $7.72 and its two-hundred day moving average price is $8.02.

Zynex (NASDAQ:ZYXI) last released its earnings results on Tuesday, March 11th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.11). Zynex had a return on equity of 13.05% and a net margin of 2.49%. During the same quarter in the prior year, the company posted $0.04 earnings per share. On average, research analysts anticipate that Zynex will post 0.2 earnings per share for the current fiscal year.

Insider Activity at Zynex

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $7.68, for a total transaction of $76,800.00. Following the completion of the transaction, the chief financial officer now directly owns 19,738 shares of the company’s stock, valued at $151,587.84. The trade was a 33.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 30,000 shares of company stock valued at $227,100 in the last quarter. Insiders own 52.13% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its holdings in shares of Zynex by 6.2% in the fourth quarter. Bank of America Corp DE now owns 24,114 shares of the company’s stock valued at $193,000 after acquiring an additional 1,407 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Zynex by 2.1% in the fourth quarter. Ameriprise Financial Inc. now owns 96,813 shares of the company’s stock valued at $775,000 after acquiring an additional 1,993 shares in the last quarter. Connors Investor Services Inc. boosted its holdings in shares of Zynex by 5.7% in the fourth quarter. Connors Investor Services Inc. now owns 29,858 shares of the company’s stock valued at $239,000 after acquiring an additional 1,608 shares in the last quarter. Lido Advisors LLC bought a new position in shares of Zynex in the fourth quarter valued at approximately $240,000. Finally, Hancock Whitney Corp boosted its holdings in Zynex by 44.1% during the fourth quarter. Hancock Whitney Corp now owns 40,986 shares of the company’s stock worth $328,000 after buying an additional 12,542 shares in the last quarter. 29.68% of the stock is owned by institutional investors and hedge funds.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.